Trevena (TRVN) Shares Gap Down to $1.41

Share on StockTwits

Trevena Inc (NASDAQ:TRVN) shares gapped down before the market opened on Tuesday . The stock had previously closed at $1.33, but opened at $1.41. Trevena shares last traded at $1.39, with a volume of 19750 shares.

TRVN has been the subject of several research reports. Zacks Investment Research upgraded Trevena from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a research note on Friday, January 18th. HC Wainwright restated a “hold” rating and issued a $1.25 target price on shares of Trevena in a research note on Thursday, March 14th. Finally, ValuEngine downgraded Trevena from a “hold” rating to a “sell” rating in a research note on Friday, May 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $4.69.

The company has a debt-to-equity ratio of 0.18, a current ratio of 3.58 and a quick ratio of 3.55. The company has a market capitalization of $130.22 million, a P/E ratio of -3.19 and a beta of 2.55.

Trevena (NASDAQ:TRVN) last issued its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. Equities analysts forecast that Trevena Inc will post -0.37 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Advisor Group Inc. boosted its stake in Trevena by 142.9% in the 1st quarter. Advisor Group Inc. now owns 17,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 10,000 shares during the period. Two Sigma Advisers LP boosted its stake in Trevena by 35.3% in the 4th quarter. Two Sigma Advisers LP now owns 62,900 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 16,400 shares during the period. Alpine Global Management LLC bought a new stake in shares of Trevena during the 1st quarter valued at about $31,000. Northern Trust Corp boosted its position in shares of Trevena by 15.2% during the 1st quarter. Northern Trust Corp now owns 156,298 shares of the biopharmaceutical company’s stock valued at $244,000 after acquiring an additional 20,592 shares during the last quarter. Finally, ExodusPoint Capital Management LP bought a new stake in shares of Trevena during the 1st quarter valued at about $46,000. Institutional investors and hedge funds own 21.54% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Macon Daily and is the property of of Macon Daily. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://macondaily.com/2019/05/16/trevena-trvn-shares-gap-down-to-1-41.html.

Trevena Company Profile (NASDAQ:TRVN)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain.

Further Reading: Portfolio Manager

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.